Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHN939 in moderate-to-severe active thyroid eye disease (China, phase III)
CTR20261926Phase 3Active
- Sponsor
- Beijing Kanghong Biological Medicine
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of KHN939 in Graves Orbitopathy (GO), sponsored by Beijing Kanghong Biological Medicine. Started May 2026; status: active.
02
Drugs
KHN939
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20261926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261926.